[1]
PolistenaB., “The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study”, GRHTA, vol. 6, no. 1, Jun. 2019.